← Eichor
Study identifier: NCT07017257 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation for Persistent Post-concussion Symptoms

Condition: Persistent Post-concussive Symptoms  ·  Sponsor: University of Liege

PhaseNA
Planned participants48
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Persistent post-concussive symptoms (PPCS) affect a significant proportion of individuals following a concussion, leading to debilitating impacts on their quality of life and work capacity. Currently, effective treatments for PPCS are limited, despite their lasting and debilitating impact. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive neuromodulation technique, holds promise as a therapeutic option by leveraging the bottom-up modulation of brain activity via the auricular branch of the vagus nerve. This study aims to evaluate the neurophysiological and clinical effects of taVNS on brain activity and symptomatology in patients with PPCS through a randomized, controlled, double-blind trial.

This description comes directly from the study's public registry record.

Talk to the study team

Mélanie Louras, MSc  ·  +32479925739  ·  melanie.louras@uliege.be

Aurore Thibaut, PT, PhD  ·  +3243233612  ·  athibaut@uliege.be

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital of LiègeLiège, Liège, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07017257